Latest News and Press Releases
Want to stay updated on the latest news?
-
WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
-
WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
-
Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success...
-
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare ventures, congratulate Tevogen Bio (“Tevogen” or “Tevogen Bio...
-
WARREN, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
-
Approximately one in three women remain HPV positive after cervical procedures for precancerous lesions.Tens of thousands of women in the US each year are diagnosed with high-grade cervical...
-
Tevogen Bio CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy
-
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
-
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
-
Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.Expanding its pipeline to include non-oncology products, an opportunistic...